ScienceLife Sciences

Off-Target Effects with Matt Gline

BiotechTV

Matt shares a biotech CEO's perspective on the news, and he interviews other leaders about management topics important to navigating the business of drug development.

Play

Open in

7 episodes
every few months
Avg 36 min
English

Episodes 7

Newest Oldest Longest

All7 Unplayed7 In progress0 Played0

S1 · E7
June 25 · 46 min
Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm
He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's M&A dynamic. Plus, his goal of being unbiased as an investor and how he tries to create an environment at Perceptive where that style is instilled in his analysts.
S1 · E6
April 23 · 41 min
Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term
He and Matt talk about portfolio construction, and the dynamics of taking on the right capital structure throughout different phases of a company's lifecycle. Neil shares early learnings from the commercial launch of Attruby, how being a commercial stage company can impact culture, and why he created the early-stage R&D focused sister company Gondola. Plus, discussing talent, intellectual property, and more.
S1 · E5
April 9 · 33 min
Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top
Reflecting on the decades-long journey at Alnylam, John Maraganore describes making it through lean times, and how far oligos and RNAi have come today. Matt asks him about championing true innovation, and what the word 'innovation' even means in today's environment. Plus, his thoughts on China, drug pricing and access, IP, AI ,and more.
S1 · E4
Jun 30, 2025 · 26 min
Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year
Philip Ross talks about the outlook for M&A in our industry, and describes the pharma revenue growth demands that will be driving it. He discusses what qualities make targets attractive, and how the industry has changed over time during the course of his career. Plus, what attracted him to Jefferies.
S1 · E3
May 8, 2025 · 37 min
Episode 3: Matt speaks with STAT News' Adam Feuerstein about the dynamics of biotech journalism and how it compares to other industries
Adam shares his background of previously covering the tech industry, and compares and contrasts it to covering biotech. He describes his philosophy of writing for investors, and how the business of journalism does and doesn't affect the types of stories he writes.
S1 · E2
Apr 10, 2025 · 33 min
Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector
One of the largest and most successful biotech investors, Dr. Aghazadeh is asked about key current events like turnover at FDA, tariffs, China, and whether he thinks biotech has a structural problem regarding how companies 'innovate' today and the different market strategies of investors.
S1 · E1
Feb 17, 2025 · 32 min
Episode 1: From SF Healthcare Week, Matt interviews Brad Loncar about M&A and China's potential impact on it
For the first episode of the new video podcast, Matt turns the tables on Brad Loncar and interviews him about his experiences and knowledge of investing in China biotech over the years. They discuss the rise of China biotech and how it might or might not be impacting M&A in the sector.

Showing 1–7 of 7 episodes

Off-Target Effects with Matt Gline

Episodes 7

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term

Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top

Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year

Episode 3: Matt speaks with STAT News' Adam Feuerstein about the dynamics of biotech journalism and how it compares to other industries

Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector

Episode 1: From SF Healthcare Week, Matt interviews Brad Loncar about M&A and China's potential impact on it